Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,692 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Dendritic cells as therapeutic agents against cancer.
Eksioglu EA, Eisen S, Reddy V. Eksioglu EA, et al. Front Biosci (Landmark Ed). 2010 Jan 1;15:321-47. doi: 10.2741/3623. Front Biosci (Landmark Ed). 2010. PMID: 20036823 Review.
Potential therapeutic role of natural killer cells in cancer.
Woan K, Reddy V. Woan K, et al. Expert Opin Biol Ther. 2007 Jan;7(1):17-29. doi: 10.1517/14712598.7.1.17. Expert Opin Biol Ther. 2007. PMID: 17150016 Review.
Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease.
Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche HU, Schold J, Wingard JR. Reddy V, et al. Blood. 2004 Jun 1;103(11):4330-5. doi: 10.1182/blood-2003-09-3325. Epub 2004 Feb 12. Blood. 2004. PMID: 14962904
Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation.
Eksioglu EA, Kielbasa J, Eisen S, Reddy V. Eksioglu EA, et al. Cytotherapy. 2011 Aug;13(7):888-96. doi: 10.3109/14653249.2011.579956. Epub 2011 May 24. Cytotherapy. 2011. PMID: 21609205 Clinical Trial.
The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V. Dunbar EM, et al. Haematologica. 2008 Dec;93(12):1852-8. doi: 10.3324/haematol.13033. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945751 Clinical Trial.
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
Cable C, Buzzeo MP, Schold JD, Khan S, Leather H, Moreb J, Jamieson K, Scornik J, Amdur RJ, Wingard JR, Reddy V. Cable C, et al. Bone Marrow Transplant. 2010 Jan;45(1):31-7. doi: 10.1038/bmt.2009.126. Epub 2009 Jun 22. Bone Marrow Transplant. 2010. PMID: 19543325
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML. Duncan CN, et al. Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006. Epub 2014 Oct 12. Biol Blood Marrow Transplant. 2015. PMID: 25316109 Free PMC article. Clinical Trial.
Diffuse osteosclerosis-associated acute myeloid leukemia.
Ward DE, Fondaw MB, Shroff SK, Reddy VS, Khaled YA. Ward DE, et al. J Clin Oncol. 2012 Jan 1;30(1):e3-4. doi: 10.1200/JCO.2011.37.4983. Epub 2011 Nov 28. J Clin Oncol. 2012. PMID: 22124108 No abstract available.
2,692 results
Jump to page
Feedback